| This week's sponsor is Pfizer. | | | |
Top Stories Wednesday, November 30, 2016 Heptares Therapeutics is set to buy fellow European G protein-coupled receptor specialist G7 Therapeutics. The takeover will give Heptares access to additional technologies to stabilize GPCRs and a research outpost in Zurich, Switzerland. Wednesday, November 30, 2016 Longwood Fund and Domain Associates have led a $19.15 million funding round for newco Axial Biotherapeutics with the aim of creating new treatments for an array of CNS disorders by harnessing the gut microbiome. Wednesday, November 30, 2016 OncoMed has posted early data on two antibodies for cancer, but investors' eyes are still focused on prospects for cancer stem cell drug tarextumab. Wednesday, November 30, 2016 Sanofi has assumed responsibility for Warp Drive Bio's aminoglycoside antibiotic program. The handover happened after Warp Drive advanced the program against drug-resistant Gram-negative infections to a milestone defined in the $750 million pact the partners penned this year. Tuesday, November 29, 2016 Carrying out contract clinical research for life science companies injects around £192 million into the U.K. National Health Service every year in income and cost-savings, says a new report. Wednesday, November 30, 2016 Almost exactly a year ago, the U.S. Patent and Trademark Office dismissed Boston Scientific’s challenges to Nevro’s patents for its spinal cord stimulation tech. Now, Nevro is hitting back, filing a patent infringement suit against Boston Sci. Wednesday, November 30, 2016 Novo Nordisk has some new data showing that its long-acting insulin Tresiba results in significantly fewer nighttime low blood sugar episodes than its nemesis Lantus, while carrying about the same risk of serious heart issues, offering a spark of good news during a tough time for Danish drugmaker. Tuesday, November 29, 2016 Sanofi and Regeneron are facing a possible delay on one potentially big drug, sarilumab, after receiving a complete response letter tied to manufacturing problems at a plant in France. But Leerink analysts think the plant’s shortcomings could spell issues for another potential blockbuster, dupilumab, an experimental, first-in-class treatment for eczema. | | | The former head of Novartis’ drugs division David Epstein has signed up to become a "special advisor" to Remedy Pharmaceuticals. Release Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos have joined forces to work on a nanotech research platform. Release Ultragenyx has posted positive data from a midstage test of its UX007 in long-chain fatty acid oxidation disorder. Release Cerecor says its phase 2 major depressive disorder test has failed, with next steps planned "at a later time." Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA DeviceTalks December 12, 2016 | Newport Beach, CA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico | 